Challenging Mycobacterium tuberculosis dormancy mechanisms and their immunodiagnostic potential  by Chaves, Alexandre Silva et al.
b r a z j i n f e c t d i s . 2 0 1 5;1  9(6):636–642
w w w.  elsev ier .com/ locate /b j id
The Brazilian Journal of
INFECTIOUS  DISEASES
Review article
Challenging  Mycobacterium  tuberculosis  dormancy
mechanisms and  their  immunodiagnostic
potential
Alexandre Silva Chaves, Michele Fernandes Rodrigues, Ana Márcia Menezes Mattos,
Henrique  Couto Teixeira ∗
Department of Parasitology, Microbiology and Immunology, Universidade Federal de Juiz de Fora, Juiz de Fora, MG, Brazil
a  r  t  i  c  l  e  i  n  f  o
Article history:
Received 15 June 2015
Accepted 17 August 2015






a  b  s  t  r  a  c  t
Mycobacterium tuberculosis is the etiologic agent of tuberculosis, one of the world’s greatest
cause of morbidity and mortality due to infectious disease. Many evolutionary mechanisms
have contributed to its high level of adaptation as a host pathogen. Prior to become dor-
mant, a group of about 50 genes related to metabolic changes are transcribed by the DosR
regulon, one of the most complex and important systems of host-pathogen interaction. This
genetic mechanism allows the mycobacteria to persist during long time periods, establish-
ing  the so-called latent infection. Even in the presence of a competent immune response,
the host cannot eliminate the pathogen, only managing to keep it surrounded by an unfa-
vorable microenvironment for its growth. However, conditions such as immunosuppression
may  reestablish optimal conditions for bacterial growth, culminating in the onset of active
disease. The interactions between the pathogen and its host are still not completely elu-cidated. Nonetheless, many studies are being carried out in order to clarify this complex
relationship, thus creating new possibilities for patient approach and laboratory screening.
© 2015 Elsevier Editora Ltda. All rights reserved.Introduction
Mycobacterium tuberculosis is the causative agent of tuber-
culosis (TB), an infectious disease that remains a major
1global health issue. Each year millions of people are
accounted for infection, ranking TB as the second leading
cause of death among infectious diseases, after the human
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1413-8670/© 2015 Elsevier Editora Ltda. All rights reserved.immunodeﬁciency virus (HIV) infection. In 2013, nine million
new cases of TB were notiﬁed leading to 1.5 million deaths
despite the availability of treatment.1
One of the hallmarks of M.  tuberculosis is the ability to
establish a latent infection, capable of long persistence in thed Immunology, Institute of Biological Sciences, Federal University
host, even in the presence of a functional immune system.2
This persistent subclinical infection is driven by a low num-
ber of bacilli, which are kept in check by the host’s immune
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ystem,3 a situation thought to exist in approximately one-
hird of the world’s population.1 Of those individuals, 5–10%
ay develop clinical manifestations of active disease at some
oint in their lifetime.4 Most TB cases occur within 2–5 years
f the initial infection, especially in young children.1 Malnutri-
ion, tobacco smoke, indoor air pollution, alcoholism, silicosis,
nsulin dependent diabetes, renal failure, malignancy, HIV
nfection, and immune suppressive treatment, are considered
isk factors for reactivation.5
An important component of a public health response
gainst TB in high-income countries is the investigation of
ontacts of known TB patients. In contrast, in low- and middle-
ncome countries this policy is still being implemented.6
n terms of prevalence, 29.1% of the contacts in high-
ncome countries are latently infected, while 1.4% have active
isease.7 In low-  and middle-income realities, 51.5% of the
ontacts have latent TB infection (LTBI), with 3.1% of con-
acts developing overt disease.7 Interestingly, in these settings,
eactivation rates of up to 40% are observed in children under 2
ears old, predominantly within the ﬁrst year after infection.8
ealthcare workers are another signiﬁcant risk group espe-
ially in low-and middle-income countries. The prevalence of
TBI among healthcare workers is, on average, 54%, empha-
izing the importance of TB control in hospitals.9 However,
here is no agreement on the most common place for LTBI
ransmission, in addition, there is no gold standard for its
iagnosis, which generates inaccuracy and misinterpretations
epending on the methodology chosen.6,10
urrently  in  use,  but  far  from  gold  standard
here are two main immunological approaches for screening
. tuberculosis latently infected individuals: the tuberculin
kin test (TST), which is an in vivo assay, and the interferon-
 release assays (IGRAs), which comprises two ex vivo
ethods.11 For the execution of the TST, a determined amount
f puriﬁed protein derivative (PPD) is injected via the intra-
ermal route into the forearm of the patient. The PPD is a
rotein extract from the culture supernatants of M.  tuberculo-
is. If the reaction is positive, there is an indication of infection.
egarding the IGRAs, there are two distinct tools, an enzyme-
inked immunosorbent assay (ELISA)-based technique, and
n enzyme-linked immunospot (ELISpot)-based method.12
heir most popular commercial versions are QuantiFERON®-
B Gold In-Tube (QFN-GIT; Cellestis Ltd, Carnegie, Victoria,
ustralia); and T-SPOT®.TB (Oxford Immunotec Ltd, Mem-
his, Tennessee, USA), respectively.13 In a general sense,
oth enzyme-linked assays verify the immunologic mem-
ry of the host.12 While the ELISA-based test determines
he concentration of IFN- in supernatants of M.  tuberculo-
is antigen-stimulated cell cultures, the ELISpot-based assay
llows a quantitative assessment of IFN--secreting cells in
esponse to M. tuberculosis-speciﬁc antigens.11
The sensitivity of the TST, which is the most widespread
est, is extremely dependent on the patient’s immunological
13tatus, being lower in immunocompromised patients. There
s growing evidence that the sensitivity of the IGRAs are higher
han that of the TST; however, the lack of studies carried out
n immunocompromised subjects and the impossibility of a5;1 9(6):636–642 637
clear differentiation between active disease and LTBI are major
setbacks.14 As another important consideration, the sensitiv-
ity of TST is also dependent on the choice of the cut-off value,
thus, entangling with the speciﬁcity, which is affected by the
cross-reactivity between M.  tuberculosis antigens and envi-
ronmental mycobacteria.15 Various groups have performed
reviews and meta-analysis of sensitivity and speciﬁcity values
to help clinicians and agencies to develop guidelines toward
the diagnosis of LTBI. According to Pai et al.,16 the sensitiv-
ity of IGRAs scored a value of 70% for QFN-GIT and 90% for
T-SPOT.TB, while TST reached a mark of 77%. Diel et al.17 ver-
iﬁed that IGRAs were more  reliable for the identiﬁcation of
non-infected individuals, as compared to TST. The speciﬁcity
for QFN-GIT, T-SPOT.TB, and TST were 99.4%, 98%, and 88.7%,
respectively.17 However, in high-incidence settings, a positive
IGRA may not necessarily indicate TB, as much as a negative
IGRA or negative TST cannot rule out the possibility of active
disease.16
In high-income countries, in which low TB rates are found,
LTBI screening is recommended in the subjects at increased
risk of developing the disease as a matter of public health.18
However the lack of clear cut-off values for serial testing and
unclear interpretation make useful tools like the IGRAS still
hard to be implemented in all realities.10,18 Besides, the exact
proportion of positive tests for LTBI and the number of patients
that still have not received preventive chemotherapy is still
unknown. Public health policies and clinical management for
the identiﬁcation and treatment of latently infected subjects
would be improved with a better understanding of the nature
of LTBI.2
The  key  mechanism  for  latent  infection
For survival and persistence in extreme conditions, M. tuber-
culosis must be able to sense environmental signals and utilize
them to trigger its adaptation machinery, then making its
endurance possible in a new ambient.19 Low oxygen tension,
oxidative stress, and NO are factors that are frequently associ-
ated with the establishment and maintenance of LTBI.20 In this
context, the transcription factor Rv3133c, named dormancy
survival regulator (DosR), directly coordinates the expression
of approximately 50 genes, which altogether make up the reg-
ulon DosR, preparing the metabolic changes that will allow
the mycobacteria to enter dormancy.21,22
Under aerobic conditions, the transcription factor PhoP
(Rv0757) is responsible for the maintenance of basal levels of
Rv3133c.23 When hypoxia is set, Rv3133c may have more  ﬁve-
fold increase compared to its original values,24 enabling the
entire regulon to be induced.23 Remarkably, the ﬁrst cellular
changes can occur under low concentrations of Rv3133c. So,
the ﬁrst genes to be transcribed are those related to protein
stability and homeostatic regulation, such as hspx (rv2031) and
rv1738, respectively, preparing the cell for further metabolic
changes.25
Though strictly aerobic, M. tuberculosis may face low oxy-
gen levels during the course of infection, typically in late
granulomas, which are characteristically avascular, inﬂamma-
tory, and necrotic. Those conditions have been demonstrated
as hypoxic.26 In vivo models that mimic  hypoxic conditions
i s . 2 0638  b r a z j i n f e c t d 
have shown that the more  oxygen is consumed, the more
mycobacterial growth decreases, until it eventually ceases.27
A decrease in both in vitro and in vivo oxygen tension leads to
a state of non-replication, which causes the latent infection
as a mechanism of adaptation.28 Given the necessary condi-
tions for the dormancy state induction, the DosR regulon is
activated through the action of two histidine kinase sensors,
DosT (Rv2027c) and DosS (Rv3132c). Both of them are capable
of associations with divalent gases such as NO, CO, and O2,
the regulators of their activity.29
The absence of aerobic respiration renders few metabolic
options to the bacilli. Thus, the induction of the DosR reg-
ulon must be triggered prior to complete hypoxia, allowing
adaptation and survival mechanisms to be transcribed and
translated right before ordinary energy sources are depleted.30
Despite its importance, the role DosR regulon plays reaches its
apex during the preparation for the dormancy state, chang-
ing energy sources and reducing energy expenditure.31 When
dormancy is fully set, another group of genes called endur-
ing hypoxic response (EHR) takes over until the conditions for
optimal growth are once more  resumed.32
To better comprehend the host-pathogen relationship dur-
ing dormancy various research groups have been carrying out
experiments to unravel the mechanisms by which M.  tuber-
culosis survives the environmental changes elicited by the
host’s immune system. Bold et al.33 demonstrated that the ﬁrst
changes in gene expression during the chronic phase would be
sufﬁcient to decrease the frequencies of protective CD4+ IFN-
+ T cells in the lungs of C57BL/6 mice. As a result of the down
regulation of genes expressed during the active growth phase
followed by the up regulation of those expressed during dor-
mancy, the antigen presenting cells are not able to perform
a proper activation of CD4+ T cells. Thus, there is not sufﬁ-
cient production of IFN- to control the infection.34 Besides,
as stated by Mehra et al.,35 the activation of the DosR prevents
the immune system to establish a proper T helper 1-type of
response against the pathogen.
However, one cannot associate the establishment of dor-
mancy with a state in which M.  tuberculosis would be fully
protected from the immune system in all situations. Actually,
as demonstrated by Mariotti et al.,36 dormant mycobacteria
lack the capacity to subvert the host immune system due to
its inability to block the phagosome maturation. Such ﬁnd-
ings could be associated with persistent antigen presentation
to CD4+ T cells by dendritic cells. However, it may be con-
sidered unexpected that dormant mycobacteria is recognized
by T lymphocytes with higher efﬁciency than active growing
mycobacteria. It is unlikely that dormant mycobacteria could
infect tissue macrophages during latency, as they do not repli-
cate and cannot invade host cells unless they reactivate to
sense the environment.36 Another mechanism for host pro-
tection against M.  tuberculosis infection was recently described
by Venkatasubramanian et al.37 A particular subset of reg-
ulatory T cells, named CD4+ CD25+ FoxP3+ D4GDI+ T cells,
was found to contribute in the contention of M. tuberculosis in
both human and murine models. These cells do not produce
immunomodulatory cytokines, such as TGF- or IL-10, secret-
ing Rho GDP dissociation inhibitor (D4GDI) instead. This factor
acts on macrophages, enhancing the production of IL-1, TNF-
, and reactive oxygen species, indirectly contributing, to DosR 1 5;1  9(6):636–642
regulon’s activation, as a mechanism of mycobacterial growth
arrest.37
Recent works like the one carried out by Ryndak et al.,38
have shed some light toward the niches where the mycobac-
teria actually actively grows. Remarkably, it was veriﬁed that
alveolar epithelial cells are interesting sites for mycobacte-
rial active growth, prior to macrophage infection.38 However,
the physical location during LTBI is poorly understood. It
is conceivable that dormant bacteria reside in cells which
have a scarce ability to act as antigen presentation cells, and
subverted macrophages in mature granulomas.39 These struc-
tures physically separate T lymphocytes from infected cells by
a ﬁbrous wall of caseum,40 limiting their interactions, creating
a reservoir for M.  tuberculosis.41
DosR  antigens  and  diagnosis
Diagnosing TB continues to be a challenge, especially in low-
income countries with high prevalence of the disease.1 Classic
methods such as sputum smears and cultures are relatively
cheap and widespread; however, their major drawbacks are
low sensitivity for direct sputum analysis and the long time
required for the culture.42 Molecular biology is also an alterna-
tive. Despite the rapid diagnosis afforded by this technique, its
relatively high cost and moderate sensitivity are factors that
make it unsuitable for all realities.43 Thus, the search for alter-
native approaches implementing new markers and antigens
capable of a better differentiation between LTBI and overt dis-
ease have become the subjects of many  research groups.1,5,42
Among the most important and well-studied DosR regulon-
encoded genes, the gene that codiﬁes for the protein Rv2031c,
also known as the 16 kDa antigen, whose levels elevate as
dormancy sets in, and is kept at low amounts during mycobac-
terial exponential growth.39,44 This antigen, as demonstrated
by Demissie et al.,45 elicited a higher IFN- response by T
cells from asymptomatic subjects with history of previous
infection by M.  tuberculosis in both Ethiopian and Gambian
populations. The opposite happened toward the recognition
of the active phase antigen ESAT-6, which was better suited for
people with active disease or people who had been in recent
contact with tuberculous patients.45 In agreement, Goletti
et al.46 observed a correlation between LTBI and higher IFN-
responses elicited by DosR-encoded antigens. The following
antigens were tested via ELISA: Rv2626c, Rv2627c, Rv2628,
Rv2031c and Rv2032. However, only Rv2628 elicited a high and
signiﬁcant response for both latently infected and recently
cured TB groups. The ability of Rv2628 for predicting LTBI
had a speciﬁcity of 87.5%, and sensitivity of 76%. As internal
control, QFN-GIT did not detect a response capable of dis-
criminating different stages of the disease. In another study,
IFN- response against mycobacterial dormancy antigens was
higher in those subjects who tested positive for TST, while the
response against the active phase antigen CFP-10 was signif-
icantly greater in people with active disease. The dormancy
antigens Rv1733c, Rv2029c, Rv2627c, and Rv2628 were the ones
that elicited the highest IFN- responses in latently infected
subjects.47
A remarkable fact concerning the dormancy related anti-
gens is that they do not show any boost effect related to
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.  bovis BCG vaccination. It was well demonstrated by Lin
t al.48 in both animal and human models for the follow-
ng antigens: Rv1733c, Rv1738, Rv2029c, Rv2031c, Rv2032c,
v2627c, and Rv2628. The main responsive cellular type to
he dormancy antigens in terms of IFN- production, is the
D4+ CD45RO+ T cells, which belongs to the T cell memory
ubtype.49 The same is also valid for the TST, characterizing a
henomenon found in individuals infected by mycobacteria,
ut not in healthy subjects. Among the best DosR encoded
ntigens recognized by T cells, the Rv1733c, Rv2029c, and
v2031c are the most expressive concerning CD4+, and CD8+
olyfunctional T cells in subjects exposed to M. tuberculosis.50
oth cellular types are phenotypically different from those
enerated by M.  bovis BCG vaccination, which are CD27+, while
hose found in latently infected individuals do not express this
arker.51
Caccamo et al.52 veriﬁed that the frequencies of polyfunc-
ional CD4+ IFN-+ IL-2+ TNF-+ T cells were signiﬁcantly
igher in patients with active disease, decreasing as
hemotherapy progresses. The post-chemotherapy pheno-
ypic pattern consisted mainly of CD4+ IFN-+ IL-2+ and in
inor proportion CD4+ IFN-+ T cells, which was the pat-
ern found in latently infected patients.53 According to Seder
t al.,53 the initial antigenic load dictates the phenotypic pat-
ern of the lymphocytes, so it is expected that the new pattern
ill be closely related to the formation of memory  cells. This
s also in accordance with the pattern of cytokines found after
hemotherapy.54
An interesting approach toward dormancy antigens is their
ssociation with humoral immunity. Thus, the serological
etection of antibodies against Rv2031, for example, would
rovide potential new markers. Raja et al.55 observed that
gA, IgG, and IgM antibodies against Rv2031c were detected in
erum of culture-positive and both smear-positive and smear-
egative TB patients, indicating that it could be used as a
creening strategy. Interestingly, the combination of IgA, IgG
nd IgM, generated sensitivities and speciﬁcities of 83% and
3%, respectively, allowing the differentiation between active
ulmonary disease and healthy subjects. In another study,
razilian healthcare workers recently exposed to M. tubercu-
osis, showed higher anti-Rv2031c IgM titers than those with
revious infection, or uninfected subjects, suggesting that
v2031c would be a suitable marker for recent infection.56
oreover, studies from our laboratory57 have shown a relation
etween successful treatment of pulmonary TB and serum
gG1 levels against Rv2031c, ESAT-6 and CFP-10 antigens. Dur-
ng the ﬁrst three months of treatment, a signiﬁcant increase
n IgG1 antibody titers against Rv2031c was noticed. However,
y the sixth month of treatment, IgG1 levels dropped to titers
omparable to the ones elicited by the healthy controls, as
ndicative of successful chemotherapy. Concerning the lev-
ls of IgG1 against ESAT-6 and CFP-10, they were already high
rior to chemotherapy, but as it progressed, they also dropped
o control levels. Apparently, this increase in antibody levels
s a consequence of the release of antigens from cytosol dur-
ng the lysis of the mycobacteria, thus increasing the titers
58f speciﬁc antibodies after the ﬁrst term of treatment. Such
ndings are also in agreement with a recent study published
y Belay et al.,59 in which the levels of IFN-, TNF-, and IL-10
n response to Rv2031c stimulation were signiﬁcantly higher5;1 9(6):636–642 639
in patients with LTBI after the beginning of the prophylactic
chemotherapy.
What  should  be  taken  into  account?
One of the most important features of M.  tuberculosis for its
success as a pathogen is its high level of adaptation to the
host.60 The consensus is that the bacteria, when in a state of
latent infection, stops growing and enters a stationary phase
due to the granuloma walling off.39 Eventually, when favorable
conditions are re-established in the surrounding environment,
the mycobacteria resumes its normal growth.39 Despite the
important role played by the granulomas during this process,
the exact localization of the dormant mycobacteria is still not
well known.61 Garton et al.61 showed that high numbers of
mycobacteria sharing typical dormancy patterns can be found
in the sputum of patients with active disease. Thus, what con-
ventionally is known as latent infection LTBI or dormant state
is in fact, part of a greater spectrum in which different levels
of replications are found.61,62
As veriﬁed by Arlehamn et al.63 in a study carried out with
latently infected subjects, the same T cell memory  pheno-
type described by Schuck et al.,49 was also accounted for the
majority of responsive T cells for both CFP-10 and Rv2031c
antigens. The phenotype in question is composed by CD4+
CD45RA− CCR7− effector memory  T cells.64 Moreover, it is
unknown whether or not there is a certain degree of replica-
tion in latently infected patients in a way that the memory
effector lymphocyte subtype is kept. However, this is the
major subtype partaking in the immune response against M.
tuberculosis.50 Still, further studies are necessary in order to
determine if this pattern of response is due to persistence
of certain antigens, an undetected bacterial replication, or to
longevity of the immune response even in the absence an
antigenic stimulation.63
The different responses of peripheral blood cells and the
ones at the site of infection is a matter of great importance.
As stated by Chiacchio et al.,65 there is a higher frequency of
monofunctional IFN--secreting effector memory  T cells spe-
ciﬁc to RD1 (active phase genic locus) antigens and to the
DosR-encoded antigen Rv2628 in the bronchoalveolar lavage
of patients with active TB than in their peripheral blood.
Taking this into consideration, the approach toward latently
infected patients possesses an interesting feature. While there
was a predominant Rv2628 response in the peripheral blood,
there were not any differences between both RD1 and DosR
antigens in the bronchoalveolar lavage. So, one can assume
that the response to a DosR antigen in patients with active
TB, and antigens related to active disease in latently infected
patients could be an indicator of the continuum spanned by
the life cycle of the mycobacteria.61,62
Another important point to be explored is the possibil-
ity of cross-reaction between dormancy antigens and those
originated from environmental non-tuberculous mycobacte-
ria, which are facultative intracellular bacteria that live in
66speciﬁc niches in the environment. Apparently, 41 of the 50
antigens codiﬁed by the DosR regulon have homologues in dif-
ferent species of environmental mycobacteria, and in some
common environmental bacteria.67 Lin et al.67 carried out an
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experiment testing subjects infected with Mycobacterium mar-
inum or Mycobacterium kansasii on the responsiveness of their
peripheral blood cells against stimulus with DosR antigens.
The results indicated that the antigens Rv1733c and Rv2627
were highly cross-reactive antigens, but despite the great level
of homology of the antigens Rv2029c, Rv2626c, and Rv2031
in environmental mycobacteria, virtually no cross-reactions
were observed.
Apart from the points previously discussed, two key
aspects should be taken into account toward the use of these
antigens as diagnostic tools: the genotype of the M. tubercu-
losis strain and the ethnicity of the population to be tested.
To exemplify this topic, Rian˜o et al.,68 observed that latently
infected subjects from Colombia produced higher IFN- levels
in response to the following DosR antigens: Rv1737c, Rv2029c,
and Rv2628. However, the antigens Rv1733c, Rv1735c, and
Rv2006 have not elicited a signiﬁcant IFN- response. In con-
trast, Rv1733c, Rv1735c, and Rv2006 were ranked among the
best recognized antigens in terms of IFN- response by latently
infected populations from South Africa, Ghana, and Uganda.69
Concluding  remarks
In this review article we brieﬂy discussed some mecha-
nisms by which M.  tuberculosis is able to keep itself at a low
metabolic proﬁle, allowing it to survive in an aggressive envi-
ronment as is frequently found in its host. Such mechanisms
work under ﬁne genetic control, and its products may affect
bacterial structure and metabolism leading to escape the
host’s immune system. As previously observed, DosR regulon-
encoded antigens may be used as a powerful factor to improve
the current understanding about the relationship between the
host immune response and the establishment of LTBI. How-
ever, the main point to be taken into consideration is that
latent infection is actually part of a greater spectrum in which
the life cycle of M.  tuberculosis is inserted. Thus, this must be
taken into consideration when analyzing the overall immune
response against the pathogen as well as in research for new
diagnostic tools for tuberculosis control.
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